Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free IMVT Stock Alerts

Immunovant (IMVT) Short Interest Ratio & Short Volume

Immunovant logo
$44.96 +0.66 (+1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$44.72 -0.24 (-0.54%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Immunovant Short Interest Overview

As of July 31, 2026, Immunovant (IMVT) had a short interest of 16.38 million shares sold short, representing 8.08% of the public float. This marks a -7.79% decrease in short interest since the prior report. The short interest ratio (days to cover) is 18.5, meaning it would take 18.5 days of the average trading volume of 1.54 million shares to cover all short positions.

Current Short Interest
16,375,679 shares
Previous Short Interest
17,758,956 shares
Change Vs. Previous Month
-7.79%
Dollar Volume Sold Short
$632.43 million
Short Interest Ratio
18.5 Days to Cover
Last Record Date
July 31, 2026
Outstanding Shares
206,550,000 shares
Short Percent of Float
8.08%
Today's Trading Volume
1,273,153 shares
Average Trading Volume
1,538,417 shares
Today's Volume Vs. Average
83%
Short Selling Immunovant?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Immunovant and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

IMVT Short Interest Over Time

IMVT Days to Cover Over Time

IMVT Percentage of Float Shorted Over Time

Immunovant Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/202616,375,679 shares $632.43 million -7.8%8.1%18.52 $38.62
7/15/202617,758,956 shares $708.23 million -1.3%8.8%16.72 $39.88
6/30/202617,991,218 shares $693.60 million -7.0%8.9%8.63 $38.55
6/15/202619,342,026 shares $646.80 million +0.7%9.6%14.09 $33.44
5/29/202619,208,923 shares $639.66 million -5.7%9.5%4.99 $33.30
5/15/202620,368,530 shares $559.93 million +9.6%10.1%16.36 $27.49
4/30/202618,590,270 shares $504.73 million -4.7%9.3%10.49 $27.15
4/15/202619,500,601 shares $534.90 million +5.8%9.7%13.82 $27.43
3/31/202618,430,920 shares $457.82 million +11.3%9.1%12.36 $24.84
3/13/202616,565,490 shares $404.36 million -1.6%8.3%16.11 $24.41
2/27/202616,835,365 shares $466.84 million -0.7%8.4%19.2 $27.73
2/13/202616,951,530 shares $436.50 million +2.8%8.4%10.18 $25.75
1/30/202616,487,739 shares $428.68 million -2.6%9.6%13.12 $26.00
1/15/202616,933,015 shares $440.26 million +4.9%9.8%9.72 $26.00
12/31/202516,135,139 shares $410.16 million +7.8%9.4%9.77 $25.42
12/15/202514,964,704 shares $389.08 million -0.7%8.7%7.15 $26.00
11/28/202515,067,824 shares $366.98 million -8.0%8.8%12.78 $24.36
11/14/202516,381,611 shares $388.90 million +1.0%9.5%10.11 $23.74
10/31/202516,214,977 shares $400.19 million -4.7%9.5%7.27 $24.68
10/15/202517,010,000 shares $304.99 million +4.6%24.1%10.6 $17.93
9/30/202516,270,000 shares $262.27 million +0.7%23.1%10.8 $16.12
9/15/202516,150,000 shares $250.81 million +3.7%22.9%11.1 $15.53
8/31/202515,570,000 shares $228.72 million -3.1%22.1%11.4 $14.69
8/15/202516,070,000 shares $244.59 million -2.2%22.8%12.4 $15.22
7/31/202516,430,000 shares $264.19 million -20.1%23.9%13 $16.08
7/15/202520,570,000 shares $359.77 million +0.6%30.0%16.6 $17.49
6/30/202520,440,000 shares $327.04 million +2.6%29.8%14.6 $16.00
6/15/202519,920,000 shares $311.95 million -8.1%29.1%12.6 $15.66
5/31/202521,680,000 shares $322.38 million +1.3%31.6%12.5 $14.87
5/15/202521,400,000 shares $297.89 million +3.3%31.4%12.7 $13.92
4/30/202520,710,000 shares $334.47 million -0.6%30.4%11.7 $16.15
4/15/202520,830,000 shares $322.24 million +5.8%30.5%11.7 $15.47
3/31/202519,690,000 shares $336.50 million +24.6%28.9%11.6 $17.09
3/15/202515,800,000 shares $308.42 million +2.7%22.8%11 $19.52
2/28/202515,390,000 shares $317.03 million +4.1%22.2%13.3 $20.60
2/15/202514,790,000 shares $300.68 million +12.5%21.3%13.2 $20.33
1/31/202513,150,000 shares $285.88 million +2.5%19.2%11.7 $21.74
1/15/202512,830,000 shares $313.05 million +4.7%21.7%13.8 $24.40
12/31/202412,260,000 shares $303.68 million -2.9%19.7%14.6 $24.77
12/15/202412,630,000 shares $331.92 million -0.3%20.3%14.9 $26.28
The $15 Gold Fund That Pays Up to $1,152/Month (Ad)

Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel

Discover the gold income fund before the next payout date
11/30/202412,670,000 shares $357.29 million -2.7%20.4%15.2 $28.20
11/15/202413,020,000 shares $346.72 million -0.6%21.0%14.5 $26.63
10/31/202413,100,000 shares $383.31 million +1.3%21.1%15.6 $29.26
10/15/202412,930,000 shares $369.15 million +2.3%20.8%14.3 $28.55
9/30/202412,640,000 shares $360.37 million +1.4%20.4%13.1 $28.51
9/15/202412,460,000 shares $369.69 million +0.6%20.1%11.9 $29.67
8/31/202412,390,000 shares $382.85 million +1.3%20.0%11.9 $30.90
8/15/202412,230,000 shares $377.66 million +9.1%19.8%10.6 $30.88
7/31/202411,210,000 shares $325.87 million +10.1%18.1%9.8 $29.07
7/15/202410,180,000 shares $310.59 million +1.6%16.5%8.9 $30.51
6/30/202410,020,000 shares $264.53 million -1.1%16.0%8.8 $26.40
6/15/202410,130,000 shares $263.38 million +10.0%16.4%8.9 $26.00
5/31/20249,210,000 shares $233.84 million -0.9%15.0%7.8 $25.39
5/15/20249,290,000 shares $287.34 million +3.7%15.3%8.7 $30.93
4/30/20248,960,000 shares $245.86 million +5.3%14.8%7.9 $27.44
4/15/20248,510,000 shares $259.30 million -5.7%14.1%7.4 $30.47
3/31/20249,020,000 shares $291.44 million -3.5%14.9%7.3 $32.31
3/15/20249,350,000 shares $285.46 million +7.7%15.3%7.1 $30.53
2/29/20248,680,000 shares $307.01 million -3.7%14.3%6.1 $35.37
2/15/20249,010,000 shares $340.58 million +8.4%14.8%6 $37.80
1/31/20248,310,000 shares $302.57 million +3.4%13.7%5.5 $36.41
1/15/20248,040,000 shares $340.57 million +7.8%13.3%5.1 $42.36
12/31/20237,460,000 shares $314.29 million -2.1%12.3%4.8 $42.13
12/15/20237,620,000 shares $325.68 million +10.6%12.6%3.1 $42.74
11/30/20236,890,000 shares $269.61 million -2.4%11.4%3.1 $39.13
11/15/20237,060,000 shares $241.73 million +5.5%11.6%3.3 $34.24
10/31/20236,690,000 shares $221.10 million -0.3%14.3%3 $33.05
10/15/20236,710,000 shares $251.02 million -8.0%14.3%3.2 $37.41
9/30/20237,290,000 shares $279.86 million +42.1%15.5%3.5 $38.39
9/15/20235,130,000 shares $111.89 million +4.7%9.7%4.6 $21.81
8/31/20234,900,000 shares $111.28 million +28.6%9.3%4.3 $22.71
8/15/20233,810,000 shares $78.18 million +2.7%7.3%3.4 $20.52
7/31/20233,710,000 shares $84.70 million +3.6%7.2%3.4 $22.83
7/15/20233,580,000 shares $74.25 million -2.7%6.9%3.2 $20.74
6/30/20233,680,000 shares $69.81 million +7.6%7.1%3.5 $18.97
6/15/20233,420,000 shares $72.26 million -0.3%6.6%3.2 $21.13
5/31/20233,430,000 shares $72.06 million -20.4%6.7%3.4 $21.01
5/15/20234,310,000 shares $79.35 million -4.9%8.4%4.6 $18.41
4/30/20234,530,000 shares $73.11 million -3.6%8.8%5.2 $16.14
4/15/20234,700,000 shares $67.07 million -3.5%9.2%5.5 $14.27
3/31/20234,870,000 shares $75.53 million +21.8%9.4%5.2 $15.51
3/15/20234,000,000 shares $61.64 million +16.6%7.6%3.9 $15.41
2/28/20233,430,000 shares $59.92 million +19.9%6.6%3.2 $17.47
2/15/20232,860,000 shares $51.85 million +23.3%5.5%2.6 $18.13
1/31/20232,320,000 shares $41.23 million -4.5%4.4%2 $17.77
1/15/20232,430,000 shares $45.20 million -32.5%4.7%2.1 $18.60
12/30/20223,600,000 shares $63.90 million +27.2%7.0%3.2 $17.75
12/15/20222,830,000 shares $43.04 million +8.0%5.5%2 $15.21
11/30/20222,620,000 shares $34.35 million -9.7%5.1%2.1 $13.11
11/15/20222,900,000 shares $38.54 million +7.8%5.6%2.6 $13.29
A letter from Shannon Stansberry (Ad)

Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel

Watch the full story and see the verified track record for yourself
10/31/20222,690,000 shares $30.13 million -11.2%6.2%2.5 $11.20
10/15/20223,030,000 shares $27.85 million +6.3%7.0%3.2 $9.19
9/30/20222,850,000 shares $15.90 million +7.1%6.5%3.4 $5.58
9/15/20222,660,000 shares $13.51 million +56.5%6.7%7.8 $5.08
8/31/20221,700,000 shares $8.76 million +9.0%4.3%5 $5.15
8/15/20221,560,000 shares $8.05 million -4.9%3.8%4.6 $5.16
7/31/20221,640,000 shares $6.76 million -9.9%4.0%5.2 $4.12
7/15/20221,820,000 shares $7.90 million +1.1%4.4%5.4 $4.34
6/30/20221,800,000 shares $7.02 million -13.0%4.4%4.9 $3.90
6/15/20222,070,000 shares $7.14 million -10.4%5.0%5 $3.45
5/31/20222,310,000 shares $9.79 million +0.9%5.6%4.5 $4.24
5/15/20222,290,000 shares $9.25 million -8.8%5.5%4.3 $4.04
4/30/20222,510,000 shares $11.57 million +3.3%6.1%4.3 $4.61
4/15/20222,430,000 shares $12.15 million +5.2%5.9%3.9 $5.00
3/31/20222,310,000 shares $12.73 million -17.5%5.6%3.3 $5.51
3/15/20222,800,000 shares $14.76 million -3.1%6.8%4.1 $5.27
2/28/20222,890,000 shares $16.13 million +8.2%7.1%4.2 $5.58
2/15/20222,670,000 shares $15.27 million +1.1%6.6%3.7 $5.72
1/31/20222,640,000 shares $18.45 million +2.7%6.5%3.7 $6.99
1/15/20222,570,000 shares $20.20 million +11.3%N/A0 $7.86
12/31/20212,310,000 shares $19.68 million -28.3%5.7%3.6 $8.52
12/15/20213,220,000 shares $25.34 million -5.6%8.0%5.4 $7.87
11/30/20213,410,000 shares $26.26 million +3.0%8.4%6.7 $7.70
11/15/20213,310,000 shares $27.08 million -10.8%8.2%6.1 $8.18
10/29/20213,710,000 shares $29.83 million +4.2%9.2%5.9 $8.04
10/15/20213,560,000 shares $31.04 million -1.9%8.8%3.6 $8.72
9/30/20213,630,000 shares $31.54 million -15.2%9.0%3.5 $8.69
9/15/20214,280,000 shares $36.51 million -5.5%10.6%4.1 $8.53
8/31/20214,530,000 shares $39.23 million -11.5%11.2%4.2 $8.66

IMVT Short Interest - Frequently Asked Questions

Short interest is the volume of Immunovant shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 16,375,679 shares of IMVT short. 8.08% of Immunovant's shares are currently sold short. Learn More on Immunovant's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMVT shares currently have a short interest ratio of 18.5. Learn More on Immunovant's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.08% of Immunovant's floating shares are currently sold short.

Immunovant saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 16,375,679 shares, a decline of 7.8% from the previous total of 17,758,956 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

8.08% of Immunovant's shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Immunovant: Biogen Inc. (3.70%), Alnylam Pharmaceuticals, Inc. (3.62%), Insmed, Inc. (5.31%), Roivant Sciences Ltd. (5.37%), Incyte Corporation (6.03%), BioNTech SE Sponsored ADR (1.21%), Moderna, Inc. (13.98%), United Therapeutics Corporation (5.92%), Genmab A/S Sponsored ADR (1.20%), BridgeBio Pharma, Inc. (13.92%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.50 billion), Invesco QQQ ($50.36 billion), iShares Russell 2000 ETF ($21.20 billion), Western Digital Corporation ($13.40 billion), SPDR S&P Biotech ETF ($11.59 billion), Nebius Group N.V. ($11.46 billion), iShares 20+ Year Treasury Bond ETF ($7.84 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.51 billion), iShares Semiconductor ETF ($6.37 billion), and Financial Select Sector SPDR Fund ($6.34 billion). View all of the most shorted stocks.

Short selling IMVT is an investing strategy that aims to generate trading profit from Immunovant as its price is falling. IMVT shares are trading up $0.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Immunovant occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMVT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMVT, twice per month. The most recent reporting period available is July, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like IMVT:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:IMVT is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/11/2026. FINRA publishes updated short interest twice a month.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel